Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dovitinib - Novartis/Oncology Venture

Drug Profile

Dovitinib - Novartis/Oncology Venture

Alternative Names: CHIR-258; Dovitinib lactate; GFKI-258; Growth factor kinase inhibitor 258; TKI 258

Latest Information Update: 30 Aug 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novartis
  • Developer Academic and Community Cancer Research United; Case Comprehensive Cancer Center; Georgetown University; National Cancer Institute (USA); Novartis; Ontario Clinical Oncology Group; University of California, Davis; University of Texas M. D. Anderson Cancer Center; University of Virginia; Yonsei University Health System
  • Class Antineoplastics; Benzimidazoles; Lactates; Piperazines; Quinolones; Small molecules
  • Mechanism of Action Fms-like tyrosine kinase 3 inhibitors; Platelet-derived growth factor beta receptor antagonists; Proto oncogene protein c-kit inhibitors; Type 3 fibroblast growth factor receptor antagonists; Vascular endothelial growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Adenoid cystic carcinoma
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Acute myeloid leukaemia; Adenoid cystic carcinoma; Breast cancer; Colorectal cancer; Endometrial cancer; Gastric cancer; Gastrointestinal stromal tumours; Glioblastoma; Haematological malignancies; Liver cancer; Malignant melanoma; Mesothelioma; Multiple myeloma; Neuroendocrine tumours; Non-small cell lung cancer; Pancreatic cancer; Prostate cancer; Renal cancer; Solid tumours; Thyroid cancer; Urogenital cancer; Von Hippel-Lindau disease

Most Recent Events

  • 15 Aug 2019 OV-SPV 2 plans phase II trials for dovitinib in undisclosed indications
  • 13 Jun 2019 Oncology Venture plans to file a new drug application with the US FDA for marketing approval of dovitinib based on existing Novartis data in renal cancer
  • 24 Aug 2018 Medical Prognosis Institute merged with Oncology Venture and the former changed its name to Oncology Venture A/S
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top